6-Phthalimino-6-desoxy-D-galaktose | 79645-36-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6-Phthalimino-6-desoxy-D-galaktose
• 英文别名: 2-[[(2R,3R,4S,5R,6S)-3,4,5,6-tetrahydroxyoxan-2-yl]methyl]isoindole-1,3-dione
• CAS: 79645-36-6
• 化学式: C₁₄H₁₅NO₇
• 分子量: 309.276
• InChiKey: OLIITCJSILFOLX-SLVJWFQDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.8
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  128
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• Glycolipid derivatives, their preparation and compositions comprising them
  申请人：Merck & Co., Inc.

  公开号：EP0028196A2

  公开（公告）日：1981-05-06

  Immunologic adjuvants are obtained by the synthesis of 6-(5-cholesten-3#-yloxy)hexyl 6-amino-6-deoxy-1-thio-β-D-galactopyranoside and its 6-deoxy-6-oleamido derivative.

  免疫佐剂是通过合成 6-(5-胆甾烯-3#-氧基)己基 6-氨基-6-脱氧-1-硫代-β-D-吡喃半乳糖苷及其 6-脱氧-6-油酰氨基衍生物获得的。
• Lipid vesicles bearing carbohydrate surfaces as lymphatic directed vehicles for therapeutic and diagnostic substances, their use and method of preparing them
  申请人：Merck & Co., Inc.

  公开号：EP0028917A2

  公开（公告）日：1981-05-20

  Lipid vesicles comprise a lipid bilayer which includes an analog of a cell-surface receptor such as dicetyl phosphate, stearylamine, 6-(5-cholesten-3β-yloxy)hexyl 1-thio-β-L-fucopyranoside, 6-(5-cholesten-3β-yloxy)hexyl 1-thio-β-D-galactopyranoside, 6-(5-cholesten- 3β-yloxy)hexyl 1-thio-a- D-mannopyranoside, 6-(5-cholesten- 3-yloxy)hexyl 2-acetamido-3-deoxy- 1-thio-β-D-galactopyranoside, 6-(5-cholesten- 3β-yloxy)hexyl 6-amino-6-deoxy-1-thio- β-D-galactopyranoside or 6-(5-cholesten- 3p-yloxy)hexyl 6-amino-6-deoxy-1- thio-a-D-mannopyranoside, together with cholesterol, distearoyl phospatidylcholine and an effective amount of a physiologically compatible radioactive tracer or a cytotoxic or therapeutic agent as a part of the vesicles. The vesicles of this invention can be administered to mammalian, including human, hosts and have been found to release the contents of the vesicles in a predetermined manner, and in some cases to be rapidly concentrated in the lymphatic system and/or liver, lungs, or spleen of the host.

  脂质囊泡由脂质双分子层组成，其中包括细胞表面受体的类似物，如磷酸二十六烷基酯、硬脂胺、6-(5-胆甾烯-3β-氧基)己基 1-硫代-β-L-吡喃葡萄糖苷、6-(5-胆甾烯-3β-氧基)己基 1-硫代-β-D-吡喃半乳糖苷、6-(5-胆甾烯-3β-氧基)己基 1-硫代-β-D-吡喃半乳糖苷、6-(5-胆甾烯-3β-氧基)己基 1-硫代-a-D-吡喃甘露糖苷、6-(5-胆甾烯-3-氧基)己基 2-乙酰氨基-3-脱氧-1-硫代-β-D-吡喃半乳糖苷、6-(5-胆甾烯-3β-氧基)己基 6-氨基-6-脱氧-1-硫代-β-D-吡喃半乳糖苷或 6-(5-胆甾烯-3p-氧基)己基 6-氨基-6-脱氧-1-硫代-a-D-吡喃甘露糖苷，以及胆固醇、二硬脂酰磷脂酰胆碱和有效量的生理相容放射性示踪剂或细胞毒性或治疗剂，作为囊泡的一部分。本发明的囊泡可以给哺乳动物（包括人类）宿主服用，并且发现囊泡中的内容物会以预定的方式释放出来，在某些情况下会迅速集中在宿主的淋巴系统和/或肝、肺或脾中。
• US4301152A
  申请人：——

  公开号：US4301152A

  公开（公告）日：1981-11-17
• US4310505A
  申请人：——

  公开号：US4310505A

  公开（公告）日：1982-01-12